FDA concludes Prilosec and Nexium safety review

The FDA has concluded that there is no increased risk of cardiac events in patients with gastroesophageal reflux disease (GERD) treated with Prilosec (omeprazole, from AstraZeneca) or Nexium (esomeprazole magnesium, from AstraZeneca). These findings are based on a comprehensive review of safety data from two long-term clinical trials comparing anti-reflux surgery with either Prilosec or Nexium treatment. The FDA also concludes that the overall benefit/risk profiles of these proton pump inhibitors remain unchanged.

For more information call (800) 236-9933 or visit www.astrazeneca-us.com.